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Background: CD248 is a cell surface glycoprotein, highly expressed by stromal cells and fibroblasts of tumors and
inflammatory lesions, but virtually undetectable in healthy adult tissues. CD248 promotes tumorigenesis, while lack
of CD248 in mice confers resistance to tumor growth. Mechanisms by which CD248 is downregulated are poorly
understood, hindering the development of anti-cancer therapies.
Methods: We sought to characterize the molecular mechanisms by which CD248 is downregulated by surveying
its expression in different cells in response to cytokines and growth factors.
Results: Only transforming growth factor (TGFβ) suppressed CD248 protein and mRNA levels in cultured fibroblasts and
vascular smooth muscle cells in a concentration- and time-dependent manner. TGFβ transcriptionally downregulated
CD248 by signaling through canonical Smad2/3-dependent pathways, but not via mitogen activated protein kinases p38
or ERK1/2. Notably, cancer associated fibroblasts (CAF) and cancer cells were resistant to TGFβ mediated suppression
of CD248.
Conclusions: The findings indicate that decoupling of CD248 regulation by TGFβ may contribute to its tumor-promoting
properties, and underline the importance of exploring the TGFβ-CD248 signaling pathway as a potential therapeutic
target for early prevention of cancer and proliferative disorders.Background
CD248, also referred to as endosialin and tumor endothe-
lial marker (TEM-1) [1] (reviewed in [2]), is a member of
a family of type I transmembrane glycoproteins containing
C-type lectin-like domains, that includes thrombomodulin
[3] and CD93 [4]. Although the mechanisms are not fully
elucidated, these molecules all modulate innate immunity,
cell proliferation and vascular homeostasis and are poten-
tial therapeutic targets for several diseases, including can-
cer, inflammatory disorders and thrombosis.
CD248 is expressed by cells of mesenchymal origin, in-
cluding murine embryonic fibroblasts (MEF), vascular
smooth muscle cells, pericytes, myofibroblasts, stromal cells
and osteoblasts [5-12]. During embryonic development,
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article, unless otherwise stated.(reviewed in [2]). However, after birth, CD248 protein levels
are dramatically downregulated [7,13-15], resulting in only
minimal expression in the healthy adult, except in the
endometrium, ovary, renal glomerulus and osteoblasts
[11,16-18].
While largely absent in normal tissues, CD248 is mark-
edly upregulated in almost all cancers. Highest expression
is found in neuroblastomas and in subsets of carcinomas,
such as breast and colon cancers, and in addition, in glio-
blastomas and mesenchymal tumors, such as fibrosarco-
mas and synovial sarcomas [8,14,15,17,19,20], where it is
mostly detected in perivascular and tumor stromal cells,
but also in the tumor cells themselves [21,22]. CD248 is
also expressed in placenta and during wound healing and
in wounds such as ulcers. It is also prominently expressed
in synovial fibroblasts during inflammatory arthritis [10].
In some tumors and in chronic kidney disease, CD248ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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poor prognosis [9,23,24]. The contributory role of CD248
to these pathologies was confirmed in gene inactivation
studies. Mice lacking CD248 are generally healthy, except
for an increase in bone mass [11,25] and incomplete post-
natal thymus development [26]. However, in several models,
they are protected against tumor growth, tumor invasive-
ness and metastasis [25,27] and they are less sensitive to
anti-collagen antibody induced arthritis [10].
While the mechanisms by which CD248 promotes
tumorigenesis and inflammation are not clearly defined,
the preceding observations have stimulated interest in ex-
ploring CD248 as a therapeutic target, primarily by using
anti-CD248 antibodies directed against its ectodomain
[19,20,28,29]. Likely due to limited knowledge of CD248
regulatory pathways, other approaches to interfere with or
suppress CD248 have not been reported. CD248 is upreg-
ulated in vitro by high cell density, serum starvation, by
the oncogene v-mos [5] and by hypoxia [30]. We previ-
ously showed that fibroblast expression of CD248 is sup-
pressed by contact with endothelial cells [27]. Otherwise,
factors which down-regulate CD248 have not heretofore
been reported, yet such insights might reveal novel sites
for therapeutic intervention.
In this study, we evaluated the effects of several cyto-
kines on the expression of CD248. We show that TGFβ
specifically and dramatically downregulates CD248 ex-
pression in normal cells of mesenchymal origin and that
this is mediated via canonical Smad-dependent intracellu-
lar signaling pathways. Notably, cancer cells and cancer
associated fibroblasts are resistant to TGFβ mediated sup-
pression of CD248. The findings suggest that CD248 not
only promotes tumorigenesis, but may be a marker of the
transition of TGFβ from a tumor suppressor to a tumor
promoter. Delineating the pathways that couple TGFβ and
CD248 may uncover novel therapeutic strategies.
Methods
Reagents
Rabbit anti-human CD248 antibodies (Cat no #18160-
1AP) were from ProteinTech (Chicago, USA); goat anti-
human actin antibodies (#sc-1616) from Santa Cruz
(USA); rabbit anti-SMAD1,5-Phospho (Cat no #9516),
rabbit anti-Smad2-Phospho (#3101), rabbit anti-ERK1/2-
phospho (#9101S), rabbit anti-p38-phospho (#9211),
rabbit anti-SMAD2/3 (#5678) and rabbit anti-SMAD3
(#9513) were from Cell Signaling (USA). Murine anti-
rabbit α-smooth muscle actin monoclonal antibodies
(#A5228) were from Sigma-Aldrich (Canada). Secondary
antibodies included goat anti-rabbit IRDye® 800 (LIC-926-
32211). Goat anti-rabbit IRDye® 680 (LIC-926-68071) or
donkey anti-goat IRDye® 680 antibodies (LIC-926-
68024) and anti-rabbit Alexa green-488 were from Licor
(Nebraska, USA).Basic fibroblast growth factor (bFGF), recombinant hu-
man transforming growth factor β-1 (TGFβ) (240-B/CF),
recombinant human bone morphogenic protein (BMP-2)
(355-BM-010/CF), recombinant human/mouse/Rat Activin
A, CF (338-AC-010/CF), recombinant rat platelet derived
growth factor-BB (PDGF) (250-BB-050), recombinant hu-
man vascular endothelial growth factor (VEGF), and
recombinant mouse interleukin-6 (IL-6) (406-ML/CF),
recombinant mouse tumor necrosis factor-α (TNF-α)
(410-MT/CF) and recombinant mouse interferon-γ
(IFN-γ) (485-MI/CF) were purchased from R&D Systems
(Minneapolis, USA). Phorbol 12-Myristate 13-Acetate
(PMA) (P1585) and α-amanitin were from Sigma-Aldrich
(Oakville, Canada). The inhibitors SB431542 (for ALK5),
SB202190 (for p38) and U0126 (for ERK1/2) were from
Tocris Biosciences, Canada.
Mice
Transgenic mice lacking CD248 (CD248KO/KO) were previ-
ously generated and genotyped as described [10]. Mice
were maintained on a C57Bl6 genetic background and cor-
responding sibling-derived wild-type mice (CD248WT/WT)
were used as controls.Cell culture
Murine embryonic fibroblasts (MEF) were isolated from
CD248WT/WT or CD248KO/KO mice as previously described
[10]. Cells were cultured in DMEM (Invitrogen, Canada)
with 10% fetal calf serum (FCS) and 1% Penicillin/Strepto-
mycin (Invitrogen, Karlsruhe, Germany) and used at pas-
sages 2-5. Upon reaching confluence, cells were incubated
for 14 hrs in low serum media (1% FCS) and then treated as
indicated in the Results with TGFβ (0.1-12 ng/ml), BMP-2
(50-100 ng/ml), PDGF (50 ng/ml), VEGF (20 ng/ml), bFGF
(10 ng/ml), IL-6 10 ng/ml), PMA (60 ng/ml), SB43152
(1 μM), and/or α-amanitin (20 μg/ml), for different time pe-
riods as noted. Using previously reported methods [31,32],
vascular smooth muscle cells (SMC) were isolated from the
aortae of CD248WT/WT or CD248KO/KO pups, cultured in
SMC growth media (Promocell, Heidelberg, Germany) with
15% FCS and 1% Penicillin/Streptomycin (Invitrogen)
and used at passages 2-5. Wehi-231 and A20 (mouse B-
lymphoma) cell lines (gift of Dr. Linda Matsuuchi, Univer-
sity of British Columbia) were cultured in RPMI media with
10% fetal calf serum (FCS), 1% Penicillin/Streptomycin and
0.1% mercaptoethanol. Normal fibroblasts (NF) derived
from normal mouse mammary glands, and cancer associ-
ated fibroblasts (CAF) from mammary carcinoma in mice
containing the MMTV-PyMT transgene [33] were provided
by Dr. Erik Saha (Cancer Research London UK Research
Institute, London, UK), and cultured in DMEM with 10%
FCS, 1% Penicillin/Streptomycin and 1% insulin-transferrin-
selenium.
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Cells were scraped from culture dishes, suspended in PBS,
pelleted by centrifugation and lysed with 50 μl RIPA buffer
(30 mM Tris–HCl, 15 mM NaCl, 1% Igepal, 0.5% deoxy-
cholate, 2 mM EDTA, 0.1% SDS). Centrifugation-cleared
lysates were quantified for protein content. Equal quan-
tities of cell lysates (25 μg) were separated by SDS-PAGE
under reducing or non-reducing conditions as noted,
using 8% and 12% low-bisacrylamide gels (acrylamide to
bis-acrylamide = 118:1). In pilot studies, these gels pro-
vided highest resolution of the bands of interest [34]. Pro-
teins were transferred to a nitrocellulose membrane and
after incubating with blocking buffer (1:1 PBS:Odyssey buf-
fer) (Licor, Nebraska, U.S.A.), they were probed with rabbit
anti-CD248 antibodies 140 μg/ml, goat anti-actin anti-
bodies, rabbit anti-Smad1-Phospho, anti-Smad2-Phospho,
anti-Smad2-Total or anti-Smad3 antibodies in blocking buf-
fer overnight. After washing and incubation of the filter
with the appropriate secondary antibodies (100 ng/ml
IRDye® 800 goat anti-rabbit or IRDye® Donkey anti-goat–
Licor, Nebraska, USA) in blocking buffer for 1 hr at room
temperature, detection was accomplished using a Licor
Odyssey® imaging system (Licor, Nebraska, USA) and inten-
sity of bands of interest were quantified relative to actin
using Licor software (Licor, Nebraska, U.S). All studies were
performed a minimum of 3 times, and representative West-
ern blots are shown.
Immunofluorescence analysis
Preconfluent cells were grown on cover slips and fixed at
room temperature with acetone (100%) for 2 minutes,
followed by a 30 minute incubation with blocking buffer
(1% BSA in PBS). Cells were then incubated with anti-
CD248 rabbit antibodies 40 μg/ml, for 1 hr followed by ex-
tensive washes and incubation with Alexa green 488 anti-
rabbit antibody (5 mg/ml) for 1 hr. The cells were washed
and fixed with antifade containing DAPI (Invitrogen,
Canada) for subsequent imaging with a confocal micro-
scopic (Nikon C2 model, Nikon, Canada).
Determination of stability of CD248 mRNA
α-Amanitin, an inhibitor of RNA-polymerase II, was used
to quantify the half-life of CD248 mRNA using previously
reported methods [35]. Briefly, 90% confluent MEF were
incubated with DMEM with 1% fetal calf serum (FCS)
overnight, after which the media was refreshed, and subse-
quently stimulated with α-Amanitin 20 μg/ml ± TGFβ for
the indicated time periods. RNA was isolated for gene ex-
pression analysis.
Gene expression analysis
RNA was isolated from the MEF and reverse transcribed
to cDNA/mRNA according to the manufacturer’s in-
structions (Qiagen RNeasy kit and QuantiTech reversetranscription kit, Hilden, Germany). Expression of CD248
mRNA was analyzed by RT-PCR and quantified with
SYBR green using real time PCR (Applied Biosystems®
Real-Time PCR Instrument, Canada). CD248 mRNA levels
were reported relative to the expression of the housekeep-
ing gene, Glyceraldehyde 3-Phosphate dehydrogenase
(GAPDH). The following amplification primers were used:
CD248 forward (5′-GGGCCCCTACCACTCCTCAGT-3′);
CD248 reverse (5′-AGGTGGGTGGACAGGGCTCAG-3′);
GAPDH forward (5′-GACCACAGTCCATGCCATCACT
GC-3′); GAPDH reverse (5′-ATGACCTTGCCCACAGC
CTTGG-3′).Animal care
Experimental animal procedures were approved by the
Institutional Animal Care Committee of the University
of British Columbia.Statistics
Experiments were performed in triplicate and data were
analyzed using Bonferroni post-test to compare replicates
(GraphPad Prism software Inc, California, USA). Error
bars on figures represent standard errors of the mean
(SEM). P < 0.05 was considered statistically significant.Results
Screen for cytokines that modulate expression of CD248
In view of the established links between CD248 and cell
proliferation, migration and invasion, we screened a
number of growth factors, cytokines and PMA for ef-
fects on the expression of CD248 by MEF. These factors
and the chosen concentrations were selected based on
the fact that all reportedly induce MEF to undergo in-
flammatory, migratory and/or proliferative changes. We
previously determined that these cells express CD248 at
readily detectable levels, as assessed by Western blot,
where it is often seen as a monomer (~150 kDa) and a
dimer (~300 kDa). An incubation time of 48 hrs was
chosen based on our previous findings that CD248-
dependent release and activation of matrix metallopro-
teinase (MMP9) induced by TFGβ was observed over
that period [10]. As seen in Figure 1A, bFGF, VEGF,
PDGF, PMA, IL-6, TNF-α, and IFN-γ had no effects on
CD248 expression. However, TGFβ suppressed expres-
sion of CD248 in MEF to almost undetectable levels
(Figure 1A). The same pattern of response was evident
in the murine fibroblast cell line 10 T1/2 (Figure 1B),
and in mouse primary aortic smooth muscle cells (SMC)
(Figure 1C), suggesting that CD248 specifically responds
to TGFβ and that the response is active in diverse cell
lines.
Figure 1 Expression of CD248 by mesenchymal cells in response to cytokines and growth factors. Murine embryonic fibroblasts (MEF)
(A), 10 T1/2 cells (B) and murine aortic smooth muscle cells (SMC) (C) were incubated for 48 hrs with FGF (10 ng/ml), VEGF (20 ng/ml), PDGF
(20 ng/ml), PMA (60 ng/ml), TGFβ (3 ng/ml), IL-6 (10 ng/ml), TNF-α (10 ng/ml), or IFN-γ (10 ng/ml). Cells were lysed and separated by SDS-PAGE
under non-reducing conditions for Western immunoblotting to detect CD248 and phosphorylated Smad2. Equal loading was confirmed with
actin control. Only TGFβ suppressed expression of CD248, while inducing phosphorylation of Smad2. Results are representative of 3 independent
experiments. Molecular weight markers in kDa are shown on the left.
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TGFβ exerts a range of cellular effects by binding to and
activating its cognate serine/threonine kinase receptors,
TGFβ type I (TGFβRI, ALK-5) and type II (TGFβRII),
which in turn mediate intracellular signaling events via
canonical Smad-dependent and Smad-independent signal-
ing pathways (e.g. p38 mitogen-activated protein kinase
(MAPK) pathway) (for reviews [36-38]). The canonical
Smad-dependent pathway results in recruitment and
phosphorylation of Smad2 and Smad3 which complex
with Smad4 to enter the nucleus and form a transcrip-
tional complex that modulates target gene expression in a
context-dependent manner. Diversity in the response to
TGFβ signaling is achieved by Smad2/3-independent,
“non-canonical” signaling pathways, which may include,
among others, activation of combinations of mitogen-
activated protein kinases ERK1/2 and p38, PI3K/Akt,
cyclo-oxygenase, Ras, RhoA, Abl and Src (for reviews
[36-38]). We characterized the pathways by which TGFβ
suppresses CD248. MEF were exposed to a range of
concentrations of TGFβ (0.1 to 12 ng/ml) for a period
of 48 hrs. Western blots of cell lysates showed that
TGFβ downregulated the expression of CD248 in a
concentration-dependent manner. As expected, TGFβ
also induced phosphorylation of Smad2 and Smad3 in a
concentration-dependent manner (Figure 2A,B). Con-
focal microscopy was used to visualize the effects of
TGFβ on expression of CD248 by MEF (Figure 2C). At48 hrs without TGFβ, CD248 was readily detected on the
surface of CD248WT/WT MEF, but was entirely absent in
TGFβ-treated cells as well as in CD248KO/KO MEF.
We next evaluated the temporal response of CD248 to a
fixed concentration of TGFβ (3 ng/ml) (Figure 3A,B) and
found that CD248 expression was suppressed in a time-
dependent manner to <50% by 6 hrs of exposure to TGFβ.
Once again, TGFβ induced phosphorylation of Smad2.
Notably, as seen in experiments using CD248KO/KO MEF
(lacking CD248) (Figure 3C), CD248 was not required for
TGFβ-mediated phosphorylation of Smad2, indicating that
CD248 is not a co-receptor for TGFβ signaling.
TGFβ suppresses CD248 mRNA accumulation
We evaluated the mechanism by which TGFβ suppresses
CD248. CD248 mRNA levels in MEF were quantified by
qRT-PCR at different time intervals following exposure
of the cells to 3 ng/ml TGFβ. TGFβ suppressed CD248
mRNA levels in a time-dependent manner and by 75 mi-
nutes, mRNA accumulation had diminished to ~50%
(Figure 4) and was ~20% by 2 hrs.
Using the RNA polymerase II inhibitor, α-amanitin
(20 μg/ml), we measured the stability of CD248 mRNA in
MEF and assessed whether it is altered by TGFβ. As seen
in Figure 4, the time-dependent reduction in CD248
mRNA with α-amanitin alone was almost identical to the
pattern seen with TGFβ alone, i.e., the half-life was deter-
mined to be approximately 75 minutes. The addition of
Figure 2 Expression of CD248 in response to increasing concentrations of TGFβ. (A) MEF were incubated for 48 hrs with increasing
concentrations of TGFβ. Expression of CD248 (seen as monomers (~160 kDa) and dimers) and phosphorylation of Smad2, were detected by
Western blot. (B) CD248 expression relative to actin expression was quantified by densitometry (n = 3 experiments) and results were normalized
to the no-treatment condition. (C) CD248 expression by MEF (wild-type, WT; or lacking CD248, KO) was detected with specific anti-CD248
antibodies after exposure to carrier (Control) or TGFβ for 48 hrs. TGFβ suppresses CD248 in a concentration-dependent manner, with simultaneous
increase in phosphorylated Smad2 and ERK1/2. Scale bar = 50 μm.
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ings suggest that TGFβ acts primarily at the level of
CD248 transcription and does not alter the stability of
CD248 mRNA.Suppression of CD248 by TGFβ is mediated by
ALK-5 signaling
In MEF, TGFβ reportedly signals exclusively through com-
plexes involving ALK5 [39]. SB431542 is a selective inhibi-
tor of TGFβ superfamily type I activin receptor-like kinase
(ALK) receptors, ALK4, ALK5 and ALK7, which does not
affect components of the ERK, JNK, or p38 MAP kinase
pathways [40]. We tested whether ALK5 is required for
TGFβ-mediated suppression of CD248. MEF were incu-
bated with the inhibitor (1 μM) for 1 hr prior to the
addition of 3 ng/ml TGFβ. Expression of CD248 at 48 hrs
was assessed by Western blot, immunofluorescence ana-
lysis and qRT-PCR (Figure 5A-C). When added alone,
neither the inhibitor SB431542 nor its vehicle DMSO, had
any effect on CD248 expression. As before, TGFβ dramat-
ically suppressed CD248, while simultaneously inducing
phosphorylation of Smad2 (Figure 5A). This effect of
TGFβ was entirely abrogated by preincubation of the cellswith SB431542. Thus, addition of TGFβ down-regulates
CD248 via activation of ALK-5.
TGFβ-mediated suppression of CD248 is independent of
ERK1/2 and p38 signaling
We also tested whether suppression of CD248 expres-
sion by TGFβ is mediated via one or more non-canonical
Smad2/3-independent pathways. Using U0126, a specific
inhibitor of ERK1/2 phosphorylation [41], we showed that
TGFβ does not rely on signaling via ERK1/2 to suppress
CD248 (Figure 6A). In a similar manner, using the p38
inhibitor, SB202190 [42], we also demonstrated that
phosphorylation of p38 is not required for TGFβ to
downregulate expression of CD248 (Figure 6B). Thus,
in MEF, TGFβ suppresses CD248 expression via signal-
ing pathways that do not require activation of these two
Smad2/3-independent pathways.
Regulation of CD248 by Bone morphogenic protein 2
(BMP2) and Activin
The TGFβ family of cytokines comprises over 35 mem-
bers, including the prototypic TGFβ isoforms (TGFβ1,
β2, β3), bone morphogenic proteins (BMPs), growth and
differentiation factors, activins and nodal. These regulate
Figure 3 Temporal response of CD248 to TGFβ. (A) MEF were incubated for 0-48 hrs with TGFβ 3 ng/ml. Expression of CD248 and phosphorylation
of Smad2, were detected by Western blot. (B) CD248 expression relative to actin expression was quantified by densitometry (n = 3 experiments) and results
were normalized to the no-treatment condition. CD248 expression decreases as Smad2 is phosphorylated. (C) CD248WT/WT (WT) or CD248KO/KO (KO) MEF
were exposed to TGFβ (0 or 3 ng/ml) for 48 hrs and lysates were Western blotted. Representative blots from 3 experiments are shown. Smad2 and ERK1/2
are phosphorylated in response to TGFβ even in cells that lack CD248.
Figure 4 Stability of CD248 mRNA is unaffected by TGFβ.
MEF were treated with TGFβ 3 ng/ml alone, α-amanatin 20 μg/ml
alone, or with a combination of TGFβ and α-amanitin as described
in Methods. CD248 mRNA levels, relative to the mRNA levels of the
housekeeping gene GAPDH, were quantified at different time intervals
by qRT-PCR. Results were normalized from 3 independent experiments,
each done in triplicate. The half-life of CD248 mRNA is approximately
75 minutes, which is unaltered by TGFβ.
Suresh Babu et al. BMC Cancer 2014, 14:113 Page 6 of 11
http://www.biomedcentral.com/1471-2407/14/113cell survival, proliferation, differentiation, adhesion, mi-
gration and death in a cell type-and context-dependent
manner. To further assess the specificity of action of
TGFβ on CD248 expression, we tested whether BMP2
and activin had similar effects. MEF were treated for 24
and 48 hrs with 50 and 100 ng/ml of activin or BMP2
(Figure 7A). At these concentrations of BMP2, Smad1
was, as expected, phosphorylated, while Smad2 was not
[43]. Notably, BMP2 had no effect on CD248 expres-
sion, and thus does not participate in its regulation
under these conditions. Activin induced phosphoryl-
ation of Smad2, which reportedly occurs via ALK-4/7
activation [44] (Figure 7B). In contrast to TGFβ, activin
caused only a slight reduction in CD248 expression
after 48 hrs of exposure.
Cancer cell lines are resistant to TGFβ suppression
of CD248
Since elevated CD248 is associated with tumorigenesis, we
tested whether TGFβ could suppress CD248 in tumor cell
lines as effectively as in the healthy non-cancerous cells
examined above. Mouse B lymphoma cell lines, Wehi-231
and A20 were incubated with TGFβ at concentrations of
3 ng/ml and 12 ng/ml for 24 hrs and 48 hrs (Figure 8).
Under these conditions, SMAD2 was phosphorylated, with
Figure 5 TGFβ-induced suppression of CD248 is mediated via canonical signaling pathways. (A, B, C) MEF were incubated for 48 hrs with
TGFβ 3 ng/ml and the ALK-inhibitor SB431542 1 μM either singly or in combination. Controls included carriers for SB431542 (DMSO) or for TGFβ
(0.1% BSA). (A) Western blots and (B) immunofluorescence were used to detect expression of CD248 (green). (C) CD248 mRNA levels were also
quantified (n = 3 experiments, each in triplicate; *p < 0.05). Results indicate that TGFβ-mediated suppression of CD248 protein and mRNA requires
integrity of canonical ALK5-Smad2 signaling pathway. Scale bar = 50 μm.
Figure 6 TGFβ-mediated suppression of CD248 via ALK5 is specific. (A, B) MEF were incubated with TGFβ (3 ng/ml) for 48 hrs in the
presence or absence of the inhibitor of phosphorylated ERK1/2, U0126 10 μM (A) or phosphorylated p38, SB202190 10 μM (B). Representative
Western blots from 3 independent experiments are shown and were used to assess the effect on CD248 expression. TGFβ-coupling to either
ERK1/2 or to p38 is not involved in its suppressive effects on CD248.
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Figure 7 Regulation of CD248 by BMP-2 and Activin. MEF were incubated with different concentrations of BMP2 (A) or activin (B) for 24 or
48 hrs. Representative Western blots from 3 independent experiments are shown and were used to assess the effect on CD248 expression.
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Wehi-231 cells (Figure 8A) and the A20 cells (Figure 8B),
there was no significant suppression of CD248 expression
in response to TGFβ. Indeed, in the latter, there was a slight
increase in CD248 in response to the TGFβ.Figure 8 Regulation of CD248 in cancer cells. (A, B) Wehi-231 (A) and A
concentrations of TGFβ for 24 or 48 hrs and lysates were assessed by Western i
phosphorylation of Smad2. Results are representative of 3 independent experim
from murine mammary tissue were exposed to TGFβ for 24 or 48 hrs and CD24
NF. CD248 mRNA levels in NF were significantly suppressed by TGFβ, whereas tWe also examined the effect of TGFβ on the expression
of CD248 by normal and cancer associated fibroblasts (NF
and CAF, respectively) that were derived from mouse
mammary tissues [33]. Protein levels of CD248 were rela-
tively low in both of these cell lines, making it difficult to20 (B) mouse lymphoma cells were incubated with different
mmunoblot. CD248 levels were minimally affected in spite of
ents. (C) Normal fibroblasts (NF) and cancer associated fibroblasts (CAF)
8 mRNA levels were quantified and normalized to levels from untreated
here was no effect on CD248 in CAF. *p < 0.05, n = 3.
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therefore quantified by qRT-PCR (Figure 8C). Following
exposure of the cells to 3 ng/ml or 12 ng/ml TGFβ for 24
and 48 hrs, CD248 mRNA accumulation was significantly
suppressed in the NF, while in contrast, there was no ef-
fect on CD248 mRNA levels in the CAF. Overall, the pre-
ceding findings indicate that the expression of CD248 in
cancer cells is resistant to regulation by TGFβ.
Discussion
Since the discovery of CD248 [45], clinical and genetic evi-
dence has pointed to it as a promoter of tumor growth
and inflammation (reviewed in [2]). Increased expression
of CD248 is detected in stromal cells surrounding most
tumors, and high levels often correlate with a poor prog-
nosis [20,23]. Means of interfering with the tumorigenic
effects of CD248 have eluded investigators due to a lack of
knowledge surrounding the regulation of CD248. This has
limited opportunities for the design of innovative thera-
peutic approaches. In this report, we show that expression
of CD248 by non-cancerous cells of mesenchymal origin
is specifically and dramatically downregulated at a tran-
scriptional and protein level by the pleiotropic cytokine,
TGFβ, and that the response is dependent on canonical
Smad2/3-dependent signaling. Notably, CD248 expression
by cancer cells and cancer associated fibroblasts is not al-
tered by TGFβ. The findings suggest that a TGFβ-based
strategy to suppress CD248 may be useful as a therapeutic
intervention to prevent early stage, but not later stage,
tumorigenesis.
Members of the TGFβ family regulate a wide range of
cellular processes (e.g. cell proliferation, differentiation, mi-
gration, apoptosis) that are highly context-dependent, i.e.,
stage of development, stage of disease, cell/tissue type and
location, microenvironmental factors, and epigenetic fac-
tors. Under normal conditions, TGFβ plays a dominant role
as a tumor suppressor at early stages of tumorigenesis, inhi-
biting cell proliferation and cell migration (reviewed in
[46,47]). TGFβ ligands signal via TGFβRI (ALK-5) and
TGFβRII. A third accessory type III receptor (TGFβRIII)
lacks kinase activity, but facilitates the tumor-suppressor
activities of TGFβ. TGFβ binds to TGFβRII which trans-
phosphorylates ALK-5. In canonical signaling, ALK-5 then
phosphorylates Smad2 and Smad3, inducing the formation
of heteromeric complexes with Smad4, for translocation
into the nucleus, interaction with transcription factors, and
regulation of promoters of several target genes [48,49]. Dis-
ruption of TGFβ signaling has been associated with several
cancers and a poor prognosis [47], and mice that lack TGFβ
spontaneously develop tumors and inflammation [50].
TGFβ signaling is not, however, restricted to Smads 2
and 3, but can couple to non-canonical (Smad2/3-inde-
pendent) effectors [48,51-54]. Recent data support the no-
tion that canonical signaling favours tumor suppression,while non-canonical signaling tips the balance, such that
TGFβ switches to become a promoter of tumor growth, in-
vasion and metastasis, overriding the tumor-suppressing
activities transmitted via Smad2/3. This dichotomous na-
ture is known as the “TGFβ Paradox”, a term coined to de-
scribe the conversion in function of TGFβ from tumor
suppressor to tumor promoter [55-57]. The mechanisms
underlying this switch are steadily being delineated, as regu-
lation of the multiple effector molecules that are coupled to
TGFβ are identified and characterized (reviewed in [47]).
Our findings suggest that CD248 may be one such TGFβ-
effector molecule that undergoes a context-dependent
change in coupling, and thus may be a potential therapeutic
target.
Upon determining that TGFβ suppresses CD248, we first
showed that the response is dependent on Smad 2 signal-
ing. This is consistent with the almost undetectable levels
of CD248 in normal tissues, its expression presumably held
in check at least in part by TGFβ’s tumor suppressor prop-
erties. The fact that TGFβ induces phosphorylation of
Smad2 in MEF that lack CD248, indicates that CD248 is
not required for Smad2 phosphorylation. Rather, in the
TGFβ-signaling pathway, CD248 is positioned “down-
stream” of Smad2/3 phosphorylation. We also showed that
CD248 is downregulated by TGFβ primarily at a transcrip-
tional level, and without affecting the stability of its mRNA.
We have not determined which regions of the CD248 pro-
moter are required for TGFβ-induced suppression. How-
ever, intriguingly, the murine promoter of the CD248 gene
contains the sequence 5′-TTTGGCGG (position −543
to −536) [5] that overlaps with a consensus E2F transcrip-
tion factor binding site. This is almost identical to the
unique Smad3 DNA binding site in the c-myc promoter
that is crucial for TGFβ-induced gene suppression [58]. De-
tailed mapping of the promoter will provide insights into
precisely how CD248 is regulated by TGFβ.
We also examined whether TGFβ coupling to non-
canonical effector molecules, ERK1/2 and p38, alters ex-
pression of CD248. Neither ERK1/2 nor p38, pathways
implicated in TGFβ-induced metastasis, affected CD248
expression. Thus, based on current data, TGFβ-induced
suppression of CD248 occurs primarily, if not exclusively,
via canonical Smad2/3 signaling.
The specificity of the response of CD248 to TGFβ ex-
tends beyond Smad2/3-related signaling. In a survey of
growth factors and cytokines, we could not identify other
factors that similarly suppress (or conversely, increase)
CD248 expression in MEF, 10 T1/2 cells or primary vascu-
lar smooth muscle cells. Even BMP2 and activin, members
of the TGFβ superfamily and pleiotropic cytokines that
also exhibit tumor promoter and suppressor activities, had
little effect on CD248 expression. Although our survey
was limited in range, concentration and time of exposure,
the findings suggest specificity, and highlight the central
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CD248 in non-cancerous cells.
Most notably, in two tumor cell lines and in cancer as-
sociated fibroblasts, the regulation of expression of CD248
was resistant to TGFβ. Indeed, in these cells, TGFβ neither
decreased nor increased CD248, suggesting a decoupling
of the regulatory link between TGFβ and CD248. Thus,
with the switch from a tumor suppressor to a tumor pro-
moter, TGFβ loses it ability to regulate CD248. Although
TGFβ does not appear to directly participate in enhancing
CD248 expression during late tumorigenesis, loss of its
ability to suppress CD248 may be relevant in tumor pro-
gression and metastasis.
Conclusions
We have shown that the tumor suppressor properties of
TGFβ, observed in early stage cancer, are likely mediated in
part via suppression of CD248, the latter which is mediated
via canonical Smad-dependent pathways. Upregulation
of CD248 might be an early detection marker of tumor
growth and metastasis, and may be valuable in monitoring
TGFβ-based therapies. The clinical relevance of under-
standing how CD248 is regulated is highlighted by ongoing
Phase 1 and 2 clinical trials in which the anti-CD248 anti-
body, MORAb-004, is being tested for efficacy in solid tu-
mors and lymphomas (www.clinicaltrials.gov). Delineating
the molecular mechanism(s) by which TGFβ loses its ability
to suppress CD248 will be key for the design of additional
therapeutic interventions to prevent and/or reduce CD248-
dependent tumor cell proliferation and metastasis.
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